Wifi-MT Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea by preventing histamine-mediated allergic responses. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, which play a significant role in airway inflammation and bronchoconstriction, making it effective in controlling asthma symptoms and improving respiratory function. The synergistic action of these agents provides comprehensive relief from allergic manifestations by targeting multiple inflammatory pathways. Wifi-MT Tablet is typically administered once daily, with or without food, as prescribed by a healthcare professional. It is well tolerated, with a low incidence of adverse effects; however, patients should be monitored for potential side effects such as headache, fatigue, or gastrointestinal disturbances. Caution is advised in individuals with hepatic impairment or hypersensitivity to components. This combination therapy offers an effective and convenient option for patients requiring simultaneous management of allergic rhinitis and asthma or chronic urticaria, enhancing overall quality of life through improved symptom control.